Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-08-23
2011-08-23
Huff, Sheela J (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387700, C530S391100, C530S391700, C530S387300
Reexamination Certificate
active
08003763
ABSTRACT:
The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications.
REFERENCES:
patent: 5208020 (1993-05-01), Chari et al.
patent: 5256643 (1993-10-01), Persico et al.
patent: 5264557 (1993-11-01), Salomon et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5650285 (1997-07-01), Salomon et al.
patent: 5654140 (1997-08-01), Persico et al.
patent: 5792616 (1998-08-01), Persico et al.
patent: 5854399 (1998-12-01), Salomon et al.
patent: 5981215 (1999-11-01), Meissner et al.
patent: 6207153 (2001-03-01), Dan et al.
patent: 6333410 (2001-12-01), Chari et al.
patent: 6335170 (2002-01-01), Orntoft
patent: 6989145 (2006-01-01), Shitara et al.
patent: 7318924 (2008-01-01), McKenzie et al.
patent: 7531174 (2009-05-01), Sanicola-Nadel et al.
patent: 2003/0232755 (2003-12-01), Williams et al.
patent: 2004/0014690 (2004-01-01), Ma et al.
patent: 2004/0176576 (2004-09-01), McKenzie et al.
patent: 2005/0208045 (2005-09-01), Vale et al.
patent: 2005/0255117 (2005-11-01), Sanicola-Nadel et al.
patent: 2008/0166341 (2008-07-01), Sanicola-Nadel et al.
patent: 2001-46066 (2001-02-01), None
patent: WO-00/06723 (2000-02-01), None
patent: WO-00/63693 (2000-10-01), None
patent: WO-01/40309 (2001-06-01), None
patent: WO-01/64754 (2001-09-01), None
patent: WO-02/16413 (2002-02-01), None
patent: WO-02/22808 (2002-03-01), None
patent: WO-02/059620 (2002-08-01), None
patent: WO-02/060955 (2002-08-01), None
patent: WO-02/077033 (2002-10-01), None
patent: WO-02/088170 (2002-11-01), None
patent: WO-02/096948 (2002-12-01), None
patent: WO-03/024392 (2003-03-01), None
patent: WO-03/083041 (2003-10-01), None
patent: WO-2006/074397 (2006-07-01), None
Sebolt-Leopold, Judith S. et al., “Development of anticancer drugs targeting the MAP kinase pathway,” Oncogene, vol. 19:6594-6599 (2000).
Ueda, Yutaka, et al., “Signal Transduction Inhibitor,” Cancer and Chemotherapy (Gan to Kagaku Ryoho), vol. 28 (5):591-600 (2001).
Weinstein-Oppenheimer, Caroline R. et al., “The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors,” Pharmacology & Therapeutics, vol. 88:229-279 (2000).
Yeo, Chang-Yeol et al., “Nodal Signals to Smads through Cripto-Dependent and Cripto-Independent Mechanisms,” Molecular Cell, vol. 7:949-957 (2001).
Japanese Office Action for Application No. 2003-580477, dated Sep. 24, 2009.
Adkins, Heather B. et al, “Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo,”The Journal of Clinical Investigation, vol. 112(4):575-587 (2003).
Bianco, Caterina, et al., “Cripto-1 Indirectly Stimulates the Tyrosine Phosphorylation oferbB-4 through a Novel Receptor,”The Journal of Biological Chemistry, vol. 274(13):8624-8629 (1999).
Brandt, Ralf, et al., “Identification and Biological Characterization of an Epidermal Growth Factor-related Protein: Cripto-1,”The Journal of Biological Chemistry, vol. 269(25):17320-17328 (1994).
Campbell, Ailsa M., “Monoclonal antibody technology,”Laboratory Techniques in Biochemistry and Molecular Biology, vol. 13, Eds. Burdon, R.H. et al, Elsevier, Amsterdam, New York, Oxford, Chapter 1, pp. 1-32 (1984).
Champier, Jacques et al., “Identification of differentially expressed genes in human pineal parenchymal tumors by microarray analysis,”Acta Neuropathol., vol. 109:306-313 (2005).
Ciardiello, Fortunato, et al., “Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides,”Oncogene, vol. 9:291-298 (1994).
Ciardiello, Fortunato et al., “Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A,”Journal of the National Cancer Institute, vol. 88(23):1770-1776 (1996).
Ciccodicola, Alfredo, et al., “Molecular characterization of a gene of the ‘EGF family’ expressed in undifferentiated human NTERA2 teratocarcinoma cells,”The EMBO Journal, vol. 8(7):1987-1991 (1989).
Dono, Rosanna et al., “Isolation and Characterization of the CRIPTO Autosomal Gene and its X-linked Related Sequence,”Am. J. Hum. Genet., vol. 49:555-565 (1991).
Dublin, Edwin A., et al., “Amphiregulin and cripto overexpression in breast cancer: relationship with prognosis and clinical and molecular variables,”International Journal of Oncology, vol. 7:617-622 (1995).
Ebert, Andreas D., et al., “Cripto-1 Induces Phosphatidylinositol 3′-Kinase-dependent Phosphorylation of AKT and Glycogen Synthase Kinase 3β in Human Cervical Carcinoma Cells,”Cancer Research, vol. 59:4502-4505 (1999).
Friess, Helmut et al., “CRIPTO, A Member of the Epidermal Growth Factor Family, is Over-expressed in Human Pancreatic Cancer and Chronic Pancratitis,”Int. J. Cancer, vol. 56:668-674 (1994).
Hentschke, Moritz et al., “Germ Cell Nuclear Factor is a Repressor ofCRIPTO-1andCRIPTO-3,” The Journal of Biological Chemistry, vol. 281(44):33497-33504 (2006).
Hu, X.F. et al., “Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways,”British Journal of Cancer, vol. 96:918-927 (2007).
Hu, X.F. et al, “Cripto monoclonal antibodies,”Drug News Perspect., vol. 18(5):293-303 (2005).
Kannan, Subha, et al., “Cripto Enhances the Tyrosine Phosphorylation and Shc and Activates Mitogen-activated Protein Kinase (MAPK) in Mammary Epithelial Cells,”The Journal of Biological Chemistry, vol. 272(6):3330-3335 (1997).
LePage, Doreen J. et al., “Inhibition of human tumor xenografts by anti-Cripto antibodies,”Proceedings of the American Association for Cancer Research, vol. 44, 2nd Ed., p. 145, No. 749 (2003).
Normanno, Nicola, et al., “Expression of amphiregulin, cripto-1, and heregulin α in human breast cancer cells,”International Journal of Oncology, vol. 2:903-911 (1993).
Panico, Luigi et al, “Differential Immunohistochemical Detection of Transforming Growth Factor α, Amphiregulin and Cripto in Human Normal and Malignant Breast Tissue,”Int. J. Cancer, vol. 65:51-56 (1996).
Paul, William E., “Structure and Function of IMmunoglobulins,”Fundamental Immunology, 3rd Edition, Raven Press, Ltd., Chpt. 9, pp. 292-295 (1993).
Qi, C.-F. et al., “Expression of transforming growth factor α, amphiregulin and cripto-1 in human breast carcinomas,”Br. J. Cancer, vol. 69(5):903-910 (1994).
Rudikoff, Stuart et al., “Single amino acid substitution altering antigen-binding specificity,”Proc. Natl. Acad. Sci. USA, vol. 79:1979-1983 (1982).
Saeki, Toshiaki, et al., “Expression of cripto-1 in human colorectal adenomas and carcinomas is related to the degree of dysplasia,”International Journal of Oncology, vol. 5:445-451 (1994).
Saeki, Toshiaki, et al., “Immunohistochemical detection of cripto-1, amphiregulin and transforming growth factor alpha in human gastric carcinomas and intestinal metaplasias,”International Journal of Oncology, vol. 5:215-223 (1994).
Salomon, D.S., et al., “The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer,”Endocrine-Related Cancer, vol. 7:199-226 (2000).
Schiffer, Susan G. et al., “Fucosylation of
Rayhorn Paul
Sanicola-Nadel Michele
Schiffer Susan Gail
Williams Kevin P.
Biogen Idec MA Inc.
Huff Sheela J
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Cripto blocking antibodies and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cripto blocking antibodies and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cripto blocking antibodies and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2664612